EYSINS, Switzerland, July 29, 2024 /PRNewswire/ — AliveDx (“Company”) is proud to announce it has received IVDR CE mark for its groundbreaking microarray immunoassay, designed for the detection of a specific IgE directed to a protein allergen in human serum. This is the Company’s first product for the evaluation of allergies, enhancing its portfolio of products beyond autoimmunity.

In November 2021, Northwestern University researchers introduced an injectable new therapy, which harnessed fast-moving “dancing molecules,” to repair tissues and reverse paralysis after severe spinal cord injuries.

A researcher at AIST, in collaboration with the Japan Medical Startup Incubation Program (JMPR) and N.B. Medical Corporation, has developed a novel anti-thrombogenic coating for stents used in the treatment of intracranial aneurysms. The details of this technology were published in Scientific Reports on July 10, 2024.

A new method for identifying the pathogens involved in sepsis cases, which could help to select optimal therapeutics, is reported in Nature. The test has the potential to reduce the turnaround times normally associated with developing treatments for infections and may improve patient outcomes.

FREMONT, Calif., July 25, 2024 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announces that it has successfully achieved ISO 13485:2016 certification. This internationally recognized standard for quality management systems is specific to the medical devices industry and signifies Alamar Biosciences’ dedication to providing the highest quality products and services to its customers.

Because of its high accuracy, laboratory-based polymerase chain reaction (PCR) testing is the gold standard for infectious disease diagnostics. However, PCR technology requires highly trained staff and costly equipment, hindering its availability, especially in low-resource settings. New research suggests a different kind of test could be more streamlined without sacrificing performance

Cysoni-XT is a temporary cardiac pacemaker from Welsh medtech company Ceryx Medical which aims to boost cardiac performance by resynchronisation of the heart and lungs, a natural phenomenon known as Respiratory Sinus Arrythmia (RSA). The system has shown a remarkable ability to boost performance and induce cardiac repair mechanisms in subjects with heart failure.